Debiopharm and NanoCarrier have signed a license and supply agreement for DACH-Platin Polymeric Micelle MediCelle technology, owned by NanoCarrier, and currently in late preclinical development by Debiopharm for use in oncology.
Subscribe to our email newsletter
Under the terms of the agreement, NanoCarrier grants Debiopharm an exclusive license, with the right to sublicense, develop and commercialize DACH-Platin Polymeric Micelle worldwide excluding Japan. Debiopharm will provide NanoCarrier exclusively with the starting material of DACH-platin and NanoCarrier will manufacture and provide DACH-Platin Polymeric Micelle solely to Debiopharm.
Debiopharm will cover costs related to the manufacture of DACH-Platin Polymeric Micelle and will pay NanoCarrier an up-front and milestones, as well as running royalties for the license. NanoCarrier will pay Debiopharm for the use of Debiopharm’s data or intellectual property upon registration in Japan. Debiopharm will be fully responsible for the development of DACH-Platin Polymeric Micelle.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.